These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 29736460)

  • 1. Idiopathic pulmonary fibrosis: Physicians' perceptions of patient treatment with recently approved drugs.
    Audibert C; Livoti C; Caze A
    Contemp Clin Trials Commun; 2016 Aug; 3():80-85. PubMed ID: 29736460
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nintedanib for the treatment of idiopathic pulmonary fibrosis.
    Varone F; Sgalla G; Iovene B; Bruni T; Richeldi L
    Expert Opin Pharmacother; 2018 Feb; 19(2):167-175. PubMed ID: 29327616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. South-West of England's Experience of the Safety and Tolerability Pirfenidone and Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis (IPF).
    Barratt SL; Mulholland S; Al Jbour K; Steer H; Gutsche M; Foley N; Srivastava R; Sharp C; Adamali HI
    Front Pharmacol; 2018; 9():1480. PubMed ID: 30618768
    [No Abstract]   [Full Text] [Related]  

  • 4. Pirfenidone, nintedanib and N-acetylcysteine for the treatment of idiopathic pulmonary fibrosis: A systematic review and meta-analysis.
    Rogliani P; Calzetta L; Cavalli F; Matera MG; Cazzola M
    Pulm Pharmacol Ther; 2016 Oct; 40():95-103. PubMed ID: 27481628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pirfenidone and Nintedanib in idiopathic pulmonary fibrosis: Real-life experience in an Italian referral centre.
    Bargagli E; Piccioli C; Rosi E; Torricelli E; Turi L; Piccioli E; Pistolesi M; Ferrari K; Voltolini L
    Pulmonology; 2019; 25(3):149-153. PubMed ID: 30236523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Absence of early metabolic response assessed by 18F-FDG PET/CT after initiation of antifibrotic drugs in IPF patients.
    Bondue B; Castiaux A; Van Simaeys G; Mathey C; Sherer F; Egrise D; Lacroix S; Huaux F; Doumont G; Goldman S
    Respir Res; 2019 Jan; 20(1):10. PubMed ID: 30646908
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histopathological and molecular analysis of idiopathic pulmonary fibrosis lungs from patients treated with pirfenidone or nintedanib.
    Zhang Y; Jones KD; Achtar-Zadeh N; Green G; Kukreja J; Xu B; Wolters PJ
    Histopathology; 2019 Jan; 74(2):341-349. PubMed ID: 30152895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Self-reported Gastrointestinal Side Effects of Antifibrotic Drugs in Dutch Idiopathic Pulmonary Fibrosis patients.
    Proesmans VLJ; Drent M; Elfferich MDP; Wijnen PAHM; Jessurun NT; Bast A
    Lung; 2019 Oct; 197(5):551-558. PubMed ID: 31440832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-Term Follow-Up of Patients With Idiopathic Pulmonary Fibrosis Treated With Pirfenidone or Nintedanib: A Real-Life Comparison Study.
    Cameli P; Refini RM; Bergantini L; d'Alessandro M; Alonzi V; Magnoni C; Rottoli P; Sestini P; Bargagli E
    Front Mol Biosci; 2020; 7():581828. PubMed ID: 33102528
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacotherapy and adjunctive treatment for idiopathic pulmonary fibrosis (IPF).
    Saito S; Alkhatib A; Kolls JK; Kondoh Y; Lasky JA
    J Thorac Dis; 2019 Sep; 11(Suppl 14):S1740-S1754. PubMed ID: 31632751
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nintedanib and pirfenidone for idiopathic pulmonary fibrosis in King Abdulaziz Medical City, Riyadh: Real-life data.
    Khan MA; Sherbini N; Alyami S; Al-Harbi A; Al-Ghamdi M; Alrajhi S; Rajendram R; Al-Jahdali H
    Ann Thorac Med; 2023; 18(1):45-51. PubMed ID: 36968327
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disease stage-related survival in idiopathic pulmonary fibrosis patients treated with nintedanib and pirfenidone: An exploratory study.
    Bocchino M; Bruzzese D; Scioscia G; Capitelli L; Tondo P; Rea G; Barbaro MPF; Lacedonia D
    Respir Med Res; 2023 Nov; 84():101013. PubMed ID: 37302161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nintedanib with Add-on Pirfenidone in Idiopathic Pulmonary Fibrosis. Results of the INJOURNEY Trial.
    Vancheri C; Kreuter M; Richeldi L; Ryerson CJ; Valeyre D; Grutters JC; Wiebe S; Stansen W; Quaresma M; Stowasser S; Wuyts WA;
    Am J Respir Crit Care Med; 2018 Feb; 197(3):356-363. PubMed ID: 28889759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of Pirfenidone and Nintedanib in a Human Lung Model of Fibrogenesis.
    Roach KM; Castells E; Dixon K; Mason S; Elliott G; Marshall H; Poblocka MA; Macip S; Richardson M; Khalfaoui L; Bradding P
    Front Pharmacol; 2021; 12():679388. PubMed ID: 34712131
    [No Abstract]   [Full Text] [Related]  

  • 15. Retrospective Analysis of Medication Utilization and Clinical Outcomes in Patients With Idiopathic Pulmonary Fibrosis Treated With Nintedanib or Pirfenidone.
    Ipatova AY; Koerner PH; Miller RT; Staskon F; Radi M
    Clin Med Insights Circ Respir Pulm Med; 2019; 13():1179548419834922. PubMed ID: 30890862
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic and treatment standards in idiopathic pulmonary fibrosis in the era of antifibrotic drugs in Poland: A real-world practice survey.
    Majewski S; Lewandowska K; Martusewicz-Boros MM; Piotrowski WJ
    Adv Respir Med; 2019; 87(6):221-230. PubMed ID: 31970724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Negative impact of anorexia and weight loss during prior pirfenidone administration on subsequent nintedanib treatment in patients with idiopathic pulmonary fibrosis.
    Ikeda S; Sekine A; Baba T; Katano T; Tabata E; Shintani R; Sadoyama S; Yamakawa H; Oda T; Okuda R; Kitamura H; Iwasawa T; Takemura T; Ogura T
    BMC Pulm Med; 2019 Apr; 19(1):78. PubMed ID: 30975118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential effects of Nintedanib and Pirfenidone on lung alveolar epithelial cell function in ex vivo murine and human lung tissue cultures of pulmonary fibrosis.
    Lehmann M; Buhl L; Alsafadi HN; Klee S; Hermann S; Mutze K; Ota C; Lindner M; Behr J; Hilgendorff A; Wagner DE; Königshoff M
    Respir Res; 2018 Sep; 19(1):175. PubMed ID: 30219058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nintedanib: evidence for its therapeutic potential in idiopathic pulmonary fibrosis.
    Inomata M; Nishioka Y; Azuma A
    Core Evid; 2015; 10():89-98. PubMed ID: 26346347
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful Concomitant Therapy with Pirfenidone and Nintedanib in Idiopathic Pulmonary Fibrosis: A Case Report.
    Hagmeyer L; Treml M; Priegnitz C; Randerath WJ
    Respiration; 2016; 91(4):327-32. PubMed ID: 27073887
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.